Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial. J of Skin [Internet]. 2022 Nov. 16 [cited 2026 May 1];6(6):s65. Available from: https://skin.dermsquared.com/skin/article/view/1820